
Oncology NEWS International
- Oncology NEWS International Vol 17 No 2
- Volume 17
- Issue 2
ONI remembers Judah Folkman, founder of angiogenesis
On January 14, Dr. Judah Folkman, founder of the field of angiogenesis, died unexpectedly at age 74 in Denver, while en route to Vancouver for a lecture. Dr. Folkman was founder and director of the Vascular Biology Program at Children's Hospital, Boston, and professor of pediatric surgery and cell biology at Harvard.
On January 14, Dr. Judah Folkman, founder of the field of angiogenesis, died unexpectedly at age 74 in Denver, while en route to Vancouver for a lecture. Dr. Folkman was founder and director of the Vascular Biology Program at Children's Hospital, Boston, and professor of pediatric surgery and cell biology at Harvard.
ONI often reported on Dr. Folkman's lectures. He was generous with the media, but liked to review articles for accuracy, especially in light of his 1998 experience when a NY Times piece heralded him as the man who would cure cancer, causing his office to be inundated with calls from the media and desperate patients.
So once when he did not respond to my email about an article, I called his office, and told his secretary he could call me at home. Later that night, my electricity was cut off during a thunderstorm, and that was when Dr. Folkman called. I answered on the only phone that was working, and using a flashlight, I wrote down his corrections. It turned out he hadn't responded to my email because his email file was so full it was frozen, and he could not bring himself to delete any emails without responding.
Articles in this issue
about 18 years ago
NLST article not balanced, critic of screening trial assertsabout 18 years ago
M.D. Anderson and AstraZeneca form neuropathic pain allianceabout 18 years ago
Good nilotinib responses in imatinib-resistant AP-CMLabout 18 years ago
Virus linked to Merkel cell carcinomaabout 18 years ago
Benefit of adjuvant RT/CT for pancreatic ca affirmedabout 18 years ago
Recurrence Score helps select node+ pts for chemoabout 18 years ago
For resectable liver mets: Preop chemotherapy or not?about 18 years ago
Plerixafor boosts stem cell mobilization in myeloma ptsabout 18 years ago
MRI shows second-hand smoke damageabout 18 years ago
Assay has high sensitivity for hard-to-detect SLN metsNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.




































